DiaMedica Therapeutics Inc. (Nasdaq: DMAC), is a clinical-stage biopharmaceutical company that is focused on developing novel treatments where there is significant unmet clinical need or where no current therapies are available, with a focus on preeclampsia, fetal growth restriction and acute ischemic stroke.
Looking for a particular DiaMedica Therapeutics Inc. employee's phone or email?
The DiaMedica Therapeutics Inc. annual revenue was $22.4 million in 2026.
Rick Pauls is the President and CEO of DiaMedica Therapeutics Inc..
31 people are employed at DiaMedica Therapeutics Inc..
DiaMedica Therapeutics Inc. is based in Minneapolis, Minnesota.
The NAICS codes for DiaMedica Therapeutics Inc. are [325, 32, 541714, 5417, 54171, 54, 541].
The SIC codes for DiaMedica Therapeutics Inc. are [283, 2833, 28, 2835].